Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial

• Published in: Journal of the American College of Cardiology 2008-02, Vol.51 (7), p.724-730
• Main Authors: Miller, Michael, MD, FACC, Cannon, Christopher P., MD, FACC, Murphy, Sabina A., MPH, Qin, Jie, MS, Ray, Kausik K., MD, MRCP, Braunwald, Eugene, MD, MACC
• Format: Article
• Language: English
• Subjects: Acute Coronary Syndrome - blood; Acute Coronary Syndrome - drug therapy; Acute Coronary Syndrome - epidemiology; Acute coronary syndromes; Anticholesteremic Agents - therapeutic use; Atorvastatin Calcium; Biological and medical sciences; Cardiology; Cardiology. Vascular system; Cardiovascular; Cardiovascular disease; Cholesterol; Cholesterol, LDL - blood; Confidence intervals; Coronary Disease - blood; Coronary Disease - epidemiology; Coronary heart disease; Diabetes; Estimates; Female; Heart; Heart attacks; Heptanoic Acids - therapeutic use; Humans; Hypertension; Internal Medicine; Lipids; Lipoproteins; Male; Medical sciences; Middle Aged; Myocardial Infarction - blood; Myocardial Infarction - epidemiology; Myocarditis. Cardiomyopathies; Obesity; Population; Pravastatin - therapeutic use; Proportional Hazards Models; Pyrroles - therapeutic use; Recurrence; Risk Assessment; Statins; Triglycerides; Triglycerides - blood; Variables
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2007.10.038

Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller, Christopher P. Cannon, Sabina A. Murphy, Jie Qin, Kausik K. Ray, Eugene Braunwald, for the PROVE IT-TIMI Investigators We evaluated the impact of triglycerides (TG) on coronary heart disease (CHD) risk after an acute coronary syndrome (ACS) in the PROVE IT-TIMI (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) 22 trial. For each 10-mg/dl on-treatment reduction in TG, the incidence of death, myocardial infarction, and recurrent ACS was significantly reduced after adjustment for low-density lipoprotein cholesterol (LDL-C) or non–high-density lipoprotein cholesterol and other covariates. We also observed a significant relationship between the percentage of TG lowering and incidence of CHD events in adjusted analysis. Achieving low TG may be an additional consideration beyond low LDL-C in patients after ACS.